Plain-English translation of NCT07459504 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing two different treatment approaches for young people with fatty liver disease — a condition where too much fat builds up in the liver. One approach uses a supplement called AMS2392, which contains essential amino acids that may help reduce liver fat and improve cholesterol levels. The other approach focuses on helping families reduce sugar in their diet through counseling with a registered dietitian.
Fatty liver disease in young people is becoming more common and can lead to serious health problems like type 2 diabetes and heart disease later in life. This study aims to find out which treatment approach works better to reduce liver fat and lower the risk of these future health problems.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the amino acid supplement or participate in a low-sugar diet program with a dietitian. You will attend study visits where you'll have blood tests and MRI scans to check your liver health and metabolism. The study uses a special design where your treatment might be adjusted based on how well the first approach is working for you, so some participants may try both treatments during the study.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
United States